檢索結果 - Richat Abbas

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

    Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer 由 Philip E. Lammers, Magdolna Dank, Riccardo Masetti, Richat Abbas, Fiona Hilton, Jennifer J. Coppola, Ira Jacobs

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

    Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer 由 Harold J. Burstein, Yan Sun, Luc Dirix, Zefei Jiang, Robert Paridaens, Antoinette R. Tan, Ahmad Awada, Anantbhushan Ranade, Shunchang Jiao, Gary K. Schwartz, Richat Abbas, Christine Powell, Kathleen Turnbull, Jennifer Vermette, Charles Zacharchuk, Rajendra Badwe

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib 由 Jorge E. Cortés, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong‐Wook Kim, Anna Turkina, Zhi-Xiang Shen, Ricardo Pasqüini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip, Carlo Gambacorti‐Passerini

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors 由 Adil Daud, Smitha Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy‐Bouxin, Poe‐Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

    A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors 由 Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Münster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: